Literature DB >> 19614841

Pharmacokinetics of monepantel and its sulfone metabolite, monepantel sulfone, after intravenous and oral administration in sheep.

D Karadzovska1, W Seewald, A Browning, M Smal, J Bouvier, J M Giraudel.   

Abstract

The pharmacokinetic properties of the developmental Amino-Acetonitrile Derivative (AAD), monepantel and its sulfone metabolite, monepantel sulfone were investigated in sheep following intravenous (i.v.) and oral administrations. The sulfone metabolite was rapidly formed and predominated over monepantel 4 h after dosing, irrespective of the route of administration. The steady-state volume of distribution, total body clearance and mean residence time of monepantel were 7.4 L/kg, 1.49 L/(kg x h) and 4.9 h, respectively and 31.2 L/kg, 0.28 L/(kg x h) and 111 h, respectively for monepantel sulfone. The overall bioavailability of monepantel was 31%, but it was demonstrated that approximately the same amount of monepantel sulfone was produced whether monepantel was given intravenously or orally (AUC((0-infinity)) oral/AUC((0-infinity)) i.v. of 94% for monepantel sulfone), making oral administration a very efficient route of administration for monepantel in terms of the amount of sulfone metabolite generated. Because monepantel sulfone is the main chemical entity present in sheep blood after monepantel administration and because it is also an active metabolite, its pharmacokinetic properties are of primary importance for the interpretation of future residue and efficacy studies. Overall, these pharmacokinetic data aid in the evaluation of monepantel as an oral anthelmintic in sheep.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19614841     DOI: 10.1111/j.1365-2885.2008.01052.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  6 in total

1.  The effect of sheep breed, age, and gender on the pharmacokinetics and efficacy of monepantel, an amino-acetonitrile derivative.

Authors:  Barry C Hosking; Ronald Kaminsky; Heinz Sager; Daniela Karadzovska; Wolfgang Seewald; Jerome M Giraudel; Jozef Vercruysse
Journal:  Parasitol Res       Date:  2009-11-07       Impact factor: 2.289

2.  A preliminary assessment of oral monepantel's tolerability and pharmacokinetics in individuals with treatment-refractory solid tumors.

Authors:  Anna Mislang; Richard Mollard; Gonzalo Tapia Rico; W Douglas Fairlie; Erinna F Lee; Tiffany J Harris; Roger Aston; Michael P Brown
Journal:  Cancer Chemother Pharmacol       Date:  2020-09-22       Impact factor: 3.333

3.  Monepantel antitumor activity is mediated through inhibition of major cell cycle and tumor growth signaling pathways.

Authors:  Farnaz Bahrami; Ahmed H Mekkawy; Samina Badar; David L Morris; Mohammad H Pourgholami
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

4.  acr-23 Encodes a monepantel-sensitive channel in Caenorhabditis elegans.

Authors:  Lucien Rufener; Nicola Bedoni; Roland Baur; Samantha Rey; Dominique A Glauser; Jacques Bouvier; Robin Beech; Erwin Sigel; Alessandro Puoti
Journal:  PLoS Pathog       Date:  2013-08-08       Impact factor: 6.823

5.  The narrow-spectrum anthelmintic oxantel is a potent agonist of a novel acetylcholine receptor subtype in whipworms.

Authors:  Tina V A Hansen; Susanna Cirera; Cédric Neveu; Elise Courtot; Claude L Charvet; Kirstine Calloe; Dan A Klaerke; Richard J Martin
Journal:  PLoS Pathog       Date:  2021-02-05       Impact factor: 6.823

6.  The Caenorhabditis elegans DEG-3/DES-2 Channel Is a Betaine-Gated Receptor Insensitive to Monepantel.

Authors:  Tina V A Hansen; Heinz Sager; Céline E Toutain; Elise Courtot; Cédric Neveu; Claude L Charvet
Journal:  Molecules       Date:  2022-01-05       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.